Abstract: Conventional medicine often focuses on managing the symptoms of chronic diseases like diabetes and musculoskeletal decay rather than fixing the underlying damage. To move from reactive to proactive care, the UAE needs a way to create therapies that actually restore tissue function. By localising stem cell production, the region can address its specific health challenges, such as age-related frailty and non-communicable diseases, without relying entirely on imported medical solutions.
The Abu Dhabi Biobank is partnering with Japan’s Human Life CORD to transform donated umbilical cord blood into active treatments. By combining the Biobank’s massive automated storage and genomic data with Japan’s proprietary stem cell technology, they are building the UAE’s first “end-to-end” clinical pathway. This means they aren’t just storing cells; they are building a specialised manufacturing facility (GMP) to turn those cells into “tailor-made” regenerative medicines that can be used in local hospitals.
Read this full article here: https://www.mediaoffice.abudhabi/en/health/abu-dhabi-biobank-partners-with-human-life-cord-japan-to-advance-stem-cell-therapies-in-uae/
